Imunopharm Technology Co., Ltd.

Chinese biotech funding backed by venture capital and private equity firms experienced a much-needed uplift over the past few weeks, thanks partly to investor interest in assets with novel modalities

China’s cell therapy market will grow into an exclusive space for domestic companies, at least over the coming years, after Gilead Sciences, Inc. on 13 September divested through Kite Pharma, Inc.

Cell therapy developers took the lion’s share of private equity and venture capital funds raised in China in October, with three firms bagging north of CNY300m ($41m) in total. On 31 October, Beijing

Since LianBio 's initial public listing on Nasdaq in the US, Chinese biotechs continued to attract substantial funding in the last two weeks of November, with mRNA technologies bagging the most atten